Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Image-Based Molecular Phenotyping of Pancreatic Ductal Adenocarcinoma.

Kaissis GA, Ziegelmayer S, Lohöfer FK, Harder FN, Jungmann F, Sasse D, Muckenhuber A, Yen HY, Steiger K, Siveke J, Friess H, Schmid R, Weichert W, Makowski MR, Braren RF.

J Clin Med. 2020 Mar 7;9(3). pii: E724. doi: 10.3390/jcm9030724.

2.

Strongyloides stercoralis hyperinfection syndrome presenting as mechanical ileus after short-course oral steroids for chronic obstructive pulmonary disease (COPD) exacerbation.

Rothe K, Katchanov J, Schneider J, Spinner CD, Phillip V, Busch DH, Tappe D, Braren R, Schmid RM, Slotta-Huspenina J.

Parasitol Int. 2020 Feb 20;76:102087. doi: 10.1016/j.parint.2020.102087. [Epub ahead of print]

PMID:
32087332
3.

Combined DCE-MRI- and FDG-PET enable histopathological grading prediction in a rat model of hepatocellular carcinoma.

Kaissis GA, Lohöfer FK, Hörl M, Heid I, Steiger K, Munoz-Alvarez KA, Schwaiger M, Rummeny EJ, Weichert W, Paprottka P, Braren R.

Eur J Radiol. 2020 Mar;124:108848. doi: 10.1016/j.ejrad.2020.108848. Epub 2020 Jan 23.

PMID:
32006931
4.

Differential Diagnosis for Pancreatic Cysts in CT Scans Using Densely-Connected Convolutional Networks.

Li H, Shi K, Reichert M, Lin K, Tselousov N, Braren R, Fu D, Schmid R, Li J, Menze B.

Conf Proc IEEE Eng Med Biol Soc. 2019 Jul;2019:2095-2098. doi: 10.1109/EMBC.2019.8856745.

PMID:
31946314
5.

Prognostic factors in hepatocellular carcinoma patients undergoing transarterial chemoembolization and radioembolization: a retrospective study.

Jeliazkova P, Umgelter A, Braren R, Kaissis G, Mustafa M, Einwächter H.

Eur J Gastroenterol Hepatol. 2019 Dec 16. doi: 10.1097/MEG.0000000000001625. [Epub ahead of print]

PMID:
31851090
6.

[A primer on radiomics].

Murray JM, Kaissis G, Braren R, Kleesiek J.

Radiologe. 2020 Jan;60(1):32-41. doi: 10.1007/s00117-019-00617-w. Review. German.

PMID:
31820014
7.

[A primer on machine learning].

Kleesiek J, Murray JM, Strack C, Kaissis G, Braren R.

Radiologe. 2020 Jan;60(1):24-31. doi: 10.1007/s00117-019-00616-x. Review. German.

PMID:
31811324
8.

Acceleration of chemical shift encoding-based water fat MRI for liver proton density fat fraction and T2* mapping using compressed sensing.

Lohöfer FK, Kaissis GA, Müller-Leisse C, Franz D, Katemann C, Hock A, Peeters JM, Rummeny EJ, Karampinos D, Braren RF.

PLoS One. 2019 Nov 15;14(11):e0224988. doi: 10.1371/journal.pone.0224988. eCollection 2019.

9.

A machine learning model for the prediction of survival and tumor subtype in pancreatic ductal adenocarcinoma from preoperative diffusion-weighted imaging.

Kaissis G, Ziegelmayer S, Lohöfer F, Algül H, Eiber M, Weichert W, Schmid R, Friess H, Rummeny E, Ankerst D, Siveke J, Braren R.

Eur Radiol Exp. 2019 Oct 17;3(1):41. doi: 10.1186/s41747-019-0119-0.

10.

Camera-based respiratory triggering improves the image quality of 3D magnetic resonance cholangiopancreatography.

Harder F, Lohöfer FK, Kaissis GA, Zoellner C, Kamal O, Katemann C, Hock A, Senegas J, Peeters JM, Rummeny EJ, Karampinos D, Braren RF.

Eur J Radiol. 2019 Nov;120:108675. doi: 10.1016/j.ejrad.2019.108675. Epub 2019 Sep 23.

PMID:
31585303
11.

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.

Kaissis G, Ziegelmayer S, Lohöfer F, Steiger K, Algül H, Muckenhuber A, Yen HY, Rummeny E, Friess H, Schmid R, Weichert W, Siveke JT, Braren R.

PLoS One. 2019 Oct 2;14(10):e0218642. doi: 10.1371/journal.pone.0218642. eCollection 2019.

12.

Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis.

Lu M, Hartmann D, Braren R, Gupta A, Wang B, Wang Y, Mogler C, Cheng Z, Wirth T, Friess H, Kleeff J, Hüser N, Sunami Y.

BMC Cancer. 2019 Sep 5;19(1):887. doi: 10.1186/s12885-019-6110-6.

13.

Progression after Immunotherapy for Fibrolamellar Carcinoma.

Bauer U, Mogler C, Braren RF, Algül H, Schmid RM, Ehmer U.

Visc Med. 2019 Mar;35(1):39-42. doi: 10.1159/000497464. Epub 2019 Feb 12.

14.

Pancreatic cancer detection and characterization-state of the art cross-sectional imaging and imaging data analysis.

Kaissis G, Braren R.

Transl Gastroenterol Hepatol. 2019 May 21;4:35. doi: 10.21037/tgh.2019.05.04. eCollection 2019. Review.

15.

Autoimmune Pancreatitis Type 1 Associated with a Pancreatic Pseudocyst.

Hesse F, Braren R, Schmid RM, Phillip V.

Case Rep Gastroenterol. 2019 Apr 9;13(1):195-199. doi: 10.1159/000499444. eCollection 2019 Jan-Apr.

16.

Magnetic resonance cholangiopancreatography at 3 Tesla: Image quality comparison between 3D compressed sensing and 2D single-shot acquisitions.

Lohöfer FK, Kaissis GA, Rasper M, Katemann C, Hock A, Peeters JM, Schlag C, Rummeny EJ, Karampinos D, Braren RF.

Eur J Radiol. 2019 Jun;115:53-58. doi: 10.1016/j.ejrad.2019.04.002. Epub 2019 Apr 15.

PMID:
31084759
17.

Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus.

Münch S, Pigorsch SU, Devečka M, Dapper H, Feith M, Friess H, Weichert W, Jesinghaus M, Braren R, Combs SE, Habermehl D.

Radiat Oncol. 2019 Apr 16;14(1):66. doi: 10.1186/s13014-019-1270-8.

18.

Borderline-resectable pancreatic adenocarcinoma: Contour irregularity of the venous confluence in pre-operative computed tomography predicts histopathological infiltration.

Kaissis GA, Lohöfer FK, Ziegelmayer S, Danner J, Jäger C, Schirren R, Ankerst D, Ceyhan GO, Friess H, Rummeny EJ, Weichert W, Braren RF.

PLoS One. 2019 Jan 2;14(1):e0208717. doi: 10.1371/journal.pone.0208717. eCollection 2019.

19.

Arterial Pseudoaneurysm within a Pancreatic Pseudocyst.

Phillip V, Braren R, Lukas N, Schmid RM, Geisler F.

Case Rep Gastroenterol. 2018 Aug 28;12(2):513-518. doi: 10.1159/000492459. eCollection 2018 May-Aug.

20.

Proteomic Characterization of the Heart and Skeletal Muscle Reveals Widespread Arginine ADP-Ribosylation by the ARTC1 Ectoenzyme.

Leutert M, Menzel S, Braren R, Rissiek B, Hopp AK, Nowak K, Bisceglie L, Gehrig P, Li H, Zolkiewska A, Koch-Nolte F, Hottiger MO.

Cell Rep. 2018 Aug 14;24(7):1916-1929.e5. doi: 10.1016/j.celrep.2018.07.048.

21.

Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus.

Münch S, Pigorsch SU, Devečka M, Dapper H, Weichert W, Friess H, Braren R, Combs SE, Habermehl D.

Radiat Oncol. 2018 Aug 2;13(1):139. doi: 10.1186/s13014-018-1085-z.

22.

Dual layer computed tomography: Reduction of metal artefacts from posterior spinal fusion using virtual monoenergetic imaging.

Dangelmaier J, Schwaiger BJ, Gersing AS, Kopp FF, Sauter A, Renz M, Riederer I, Braren R, Pfeiffer D, Fingerle A, Rummeny EJ, Noël PB.

Eur J Radiol. 2018 Aug;105:195-203. doi: 10.1016/j.ejrad.2018.05.034. Epub 2018 Jun 8.

PMID:
30017279
23.

Spectral Computed Tomography Angiography With a Gadolinium-based Contrast Agent: First Clinical Imaging Results in Cardiovascular Applications.

Nadjiri J, Pfeiffer D, Straeter AS, Noël PB, Fingerle A, Eckstein HH, Laugwitz KL, Rummeny EJ, Braren R, Rasper M.

J Thorac Imaging. 2018 Jul;33(4):246-253. doi: 10.1097/RTI.0000000000000335.

PMID:
29863589
24.

Dual-layer spectral computed tomography: Virtual non-contrast in comparison to true non-contrast images.

Sauter AP, Muenzel D, Dangelmaier J, Braren R, Pfeiffer F, Rummeny EJ, Noël PB, Fingerle AA.

Eur J Radiol. 2018 Jul;104:108-114. doi: 10.1016/j.ejrad.2018.05.007. Epub 2018 May 10.

PMID:
29857855
25.

Improved detection rates and treatment planning of head and neck cancer using dual-layer spectral CT.

Lohöfer FK, Kaissis GA, Köster FL, Ziegelmayer S, Einspieler I, Gerngross C, Rasper M, Noel PB, Koerdt S, Fichter A, Rummeny EJ, Braren RF.

Eur Radiol. 2018 Dec;28(12):4925-4931. doi: 10.1007/s00330-018-5511-2. Epub 2018 May 28.

PMID:
29808428
26.

Accuracy of iodine quantification in dual-layer spectral CT: Influence of iterative reconstruction, patient habitus and tube parameters.

Sauter AP, Kopp FK, Münzel D, Dangelmaier J, Renz M, Renger B, Braren R, Fingerle AA, Rummeny EJ, Noël PB.

Eur J Radiol. 2018 May;102:83-88. doi: 10.1016/j.ejrad.2018.03.009. Epub 2018 Mar 8.

PMID:
29685549
27.

Assessment of quantification accuracy and image quality of a full-body dual-layer spectral CT system.

Ehn S, Sellerer T, Muenzel D, Fingerle AA, Kopp F, Duda M, Mei K, Renger B, Herzen J, Dangelmaier J, Schwaiger BJ, Sauter A, Riederer I, Renz M, Braren R, Rummeny EJ, Pfeiffer F, Noël PB.

J Appl Clin Med Phys. 2018 Jan;19(1):204-217. doi: 10.1002/acm2.12243. Epub 2017 Dec 20.

28.

Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.

Trajkovic-Arsic M, Heid I, Steiger K, Gupta A, Fingerle A, Wörner C, Teichmann N, Sengkwawoh-Lueong S, Wenzel P, Beer AJ, Esposito I, Braren R, Siveke JT.

Sci Rep. 2017 Dec 6;7(1):17038. doi: 10.1038/s41598-017-16826-z.

29.

Combined PET/MRI: Global Warming-Summary Report of the 6th International Workshop on PET/MRI, March 27-29, 2017, Tübingen, Germany.

Bailey DL, Pichler BJ, Gückel B, Antoch G, Barthel H, Bhujwalla ZM, Biskup S, Biswal S, Bitzer M, Boellaard R, Braren RF, Brendle C, Brindle K, Chiti A, la Fougère C, Gillies R, Goh V, Goyen M, Hacker M, Heukamp L, Knudsen GM, Krackhardt AM, Law I, Morris JC, Nikolaou K, Nuyts J, Ordonez AA, Pantel K, Quick HH, Riklund K, Sabri O, Sattler B, Troost EGC, Zaiss M, Zender L, Beyer T.

Mol Imaging Biol. 2018 Feb;20(1):4-20. doi: 10.1007/s11307-017-1123-5.

30.

Imaging and targeted therapy of pancreatic ductal adenocarcinoma using the theranostic sodium iodide symporter (NIS) gene.

Schmohl KA, Gupta A, Grünwald GK, Trajkovic-Arsic M, Klutz K, Braren R, Schwaiger M, Nelson PJ, Ogris M, Wagner E, Siveke JT, Spitzweg C.

Oncotarget. 2017 May 16;8(20):33393-33404. doi: 10.18632/oncotarget.16499.

31.

Integrin-Targeted Hybrid Fluorescence Molecular Tomography/X-ray Computed Tomography for Imaging Tumor Progression and Early Response in Non-Small Cell Lung Cancer.

Ma X, Phi Van V, Kimm MA, Prakash J, Kessler H, Kosanke K, Feuchtinger A, Aichler M, Gupta A, Rummeny EJ, Eisenblätter M, Siveke J, Walch AK, Braren R, Ntziachristos V, Wildgruber M.

Neoplasia. 2017 Jan;19(1):8-16. doi: 10.1016/j.neo.2016.11.009. Epub 2016 Dec 7.

32.

Targeting PI3K/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo.

Lee M, Minaskan N, Wiedemann T, Irmler M, Beckers J, Yousefi BH, Kaissis G, Braren R, Laitinen I, Pellegata NS.

Endocr Relat Cancer. 2017 Jan;24(1):1-15. Epub 2016 Nov 3.

PMID:
27811202
33.

Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer.

Heid I, Steiger K, Trajkovic-Arsic M, Settles M, Eßwein MR, Erkan M, Kleeff J, Jäger C, Friess H, Haller B, Steingötter A, Schmid RM, Schwaiger M, Rummeny EJ, Esposito I, Siveke JT, Braren RF.

Clin Cancer Res. 2017 Mar 15;23(6):1461-1470. doi: 10.1158/1078-0432.CCR-15-2432. Epub 2016 Sep 23.

34.

Tumor Uptake of Anti-CD20 Fabs Depends on Tumor Perfusion.

Mendler CT, Feuchtinger A, Heid I, Aichler M, D'Alessandria C, Pirsig S, Blechert B, Wester HJ, Braren R, Walch A, Skerra A, Schwaiger M.

J Nucl Med. 2016 Dec;57(12):1971-1977. Epub 2016 Jul 14.

35.

Membranous CD24 drives the epithelial phenotype of pancreatic cancer.

Lubeseder-Martellato C, Hidalgo-Sastre A, Hartmann C, Alexandrow K, Kamyabi-Moghaddam Z, Sipos B, Wirth M, Neff F, Reichert M, Heid I, Schneider G, Braren R, Schmid RM, Siveke JT.

Oncotarget. 2016 Aug 2;7(31):49156-49168. doi: 10.18632/oncotarget.9402.

36.

Multiparametric human hepatocellular carcinoma characterization and therapy response evaluation by hyperpolarized (13) C MRSI.

Düwel S, Durst M, Gringeri CV, Kosanke Y, Gross C, Janich MA, Haase A, Glaser SJ, Schwaiger M, Schulte RF, Braren R, Menzel MI.

NMR Biomed. 2016 Jul;29(7):952-60. doi: 10.1002/nbm.3561. Epub 2016 May 16.

PMID:
27195474
37.

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats.

Altomonte J, Muñoz-Álvarez KA, Shinozaki K, Baumgartner C, Kaissis G, Braren R, Ebert O.

J Vis Exp. 2016 Apr 15;(110). doi: 10.3791/53757.

38.

Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice.

Maresch R, Mueller S, Veltkamp C, Öllinger R, Friedrich M, Heid I, Steiger K, Weber J, Engleitner T, Barenboim M, Klein S, Louzada S, Banerjee R, Strong A, Stauber T, Gross N, Geumann U, Lange S, Ringelhan M, Varela I, Unger K, Yang F, Schmid RM, Vassiliou GS, Braren R, Schneider G, Heikenwalder M, Bradley A, Saur D, Rad R.

Nat Commun. 2016 Feb 26;7:10770. doi: 10.1038/ncomms10770.

39.

Modeling Therapy Response and Spatial Tissue Distribution of Erlotinib in Pancreatic Cancer.

Grüner BM, Winkelmann I, Feuchtinger A, Sun N, Balluff B, Teichmann N, Herner A, Kalideris E, Steiger K, Braren R, Aichler M, Esposito I, Schmid RM, Walch A, Siveke JT.

Mol Cancer Ther. 2016 May;15(5):1145-52. doi: 10.1158/1535-7163.MCT-15-0165. Epub 2016 Jan 28.

40.

[Multifocal tumors in a 56-year-old male patient].

Kaissis G, Eiber M, Becker V, Holzapfel K, Rummeny EJ, Braren R.

Radiologe. 2015 Nov;55(11):1009-13. doi: 10.1007/s00117-015-0037-y. German. No abstract available.

PMID:
26515284
41.

CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice.

Weber J, Öllinger R, Friedrich M, Ehmer U, Barenboim M, Steiger K, Heid I, Mueller S, Maresch R, Engleitner T, Gross N, Geumann U, Fu B, Segler A, Yuan D, Lange S, Strong A, de la Rosa J, Esposito I, Liu P, Cadiñanos J, Vassiliou GS, Schmid RM, Schneider G, Unger K, Yang F, Braren R, Heikenwälder M, Varela I, Saur D, Bradley A, Rad R.

Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13982-7. doi: 10.1073/pnas.1512392112. Epub 2015 Oct 27.

42.

Next-generation metabolic imaging in pancreatic cancer.

Braren RF, Siveke JT.

Gut. 2016 Mar;65(3):367-9. doi: 10.1136/gutjnl-2015-310518. Epub 2015 Oct 13. No abstract available.

PMID:
26464413
43.

[Metastasis of pancreatic tumors].

Häberle L, Braren R, Schlitter AM, Esposito I.

Pathologe. 2015 Nov;36 Suppl 2:176-80. doi: 10.1007/s00292-015-0077-0. Review. German.

PMID:
26391249
44.

Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.

Mazur PK, Herner A, Mello SS, Wirth M, Hausmann S, Sánchez-Rivera FJ, Lofgren SM, Kuschma T, Hahn SA, Vangala D, Trajkovic-Arsic M, Gupta A, Heid I, Noël PB, Braren R, Erkan M, Kleeff J, Sipos B, Sayles LC, Heikenwalder M, Heßmann E, Ellenrieder V, Esposito I, Jacks T, Bradner JE, Khatri P, Sweet-Cordero EA, Attardi LD, Schmid RM, Schneider G, Sage J, Siveke JT.

Nat Med. 2015 Oct;21(10):1163-71. doi: 10.1038/nm.3952. Epub 2015 Sep 21.

45.

Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.

Nitsche U, Wenzel P, Siveke JT, Braren R, Holzapfel K, Schlitter AM, Stöß C, Kong B, Esposito I, Erkan M, Michalski CW, Friess H, Kleeff J.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1212-20. doi: 10.1245/s10434-015-4851-2. Epub 2015 Sep 8.

PMID:
26350368
46.

Outcomes of resections for pancreatic adenocarcinoma with suspected venous involvement: a single center experience.

Michalski CW, Kong B, Jäger C, Kloe S, Beier B, Braren R, Esposito I, Erkan M, Friess H, Kleeff J.

BMC Surg. 2015 Aug 22;15:100. doi: 10.1186/s12893-015-0086-1.

47.

Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.

Groß C, Steiger K, Sayyed S, Heid I, Feuchtinger A, Walch A, Heß J, Unger K, Zitzelsberger H, Settles M, Schlitter AM, Dworniczak J, Altomonte J, Ebert O, Schwaiger M, Rummeny E, Steingötter A, Esposito I, Braren R.

Clin Cancer Res. 2015 Oct 1;21(19):4440-50. doi: 10.1158/1078-0432.CCR-14-2018. Epub 2015 May 20.

48.

Characterization of magnetic viral complexes for targeted delivery in oncology.

Almstätter I, Mykhaylyk O, Settles M, Altomonte J, Aichler M, Walch A, Rummeny EJ, Ebert O, Plank C, Braren R.

Theranostics. 2015 Mar 18;5(7):667-85. doi: 10.7150/thno.10438. eCollection 2015.

49.

Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas.

Lee M, Wiedemann T, Gross C, Leinhäuser I, Roncaroli F, Braren R, Pellegata NS.

Clin Cancer Res. 2015 Jul 15;21(14):3204-15. doi: 10.1158/1078-0432.CCR-15-0288. Epub 2015 Apr 2.

50.

Multimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins.

Meier R, Braren R, Kosanke Y, Bussemer J, Neff F, Wildgruber M, Schwarzenböck S, Frank A, Haller B, Hohlbaum AM, Schwaiger M, Gille H, Rummeny EJ, Beer AJ.

PLoS One. 2014 May 6;9(5):e94972. doi: 10.1371/journal.pone.0094972. eCollection 2014.

Supplemental Content

Loading ...
Support Center